Precision Medicine (PM) and Artificial Intelligence (AI) algorithms – risk of bias in treatment | Diaceutics

Precision Medicine (PM) and Artificial Intelligence (AI) algorithms – risk of bias in treatment

June 26th, 2018

Diaceutics using AI Intelligence

Precision medicine is more impactful when we build a story through use of a complete and meaningful dataset. Many publications discuss the idea that precision medicine relies on smart technology and this is true. At Diaceutics we believe that smart technology needs to be paired with the right dataset.  

For predictive algorithms in precision healthcare to work well, we need to start with what works well for individuals and deep learning algorithms can be used to classify and categorize data. When we combine deep learning with reinforcement learning – long term self-learning through trial and error – we expect the end results to be meaningful or to tell a story, but that may or may not meet expectations. 

Volumes of organized data collected systematically over time allow us to build a story so that we can remark that ‘in patients like this, in the recent past, these are the things that have worked well’. Not all data, however, is collected systematically. There are ethical concerns linked to underrepresentation of patient groups that might need to be addressed e.g. some ethnic/socioeconomic/age groups may be less likely to consent to participating in a data sharing project. Therefore, patient consented data sets risk some patient groups being underrepresented.  A predictive algorithm used in a computer aided diagnostic tool, developed through use of such potentially not fully representative data sets, might lead to biased algorithms and therefore benefits for one patient group, prospective harm in an underrepresented patient group and a risk of further inequalities in access to healthcare. A broader more global dataset that captures details about demographics would be ideal.  

Clinical laboratory data can be regarded as real-world data and is expected to tell a more complete story in terms of describing patient treatment pathways in the population at large.  We know that individual laboratories have a unique view of the populations they serve. Content gathered is patient-centric and linked to biomarkers or surrogate biomarkers.  

The benefit of clinical laboratory data used to improve the diagnostic process is invaluable and leads to precision or targeted treatments – getting patients on the right drug at the right time.  

The value and impact of big data within the diagnostic and treatment journey of patients is an area of interest and a greater focus needs to be placed on how this data can be used.  

An AI enabled care pathway can certainly lead to faster and more reliable follow up for some patients, so long as we ensure that the dataset is meaningful in the design of the diagnostic and treatment algorithms and improves healthcare for the many not the few. 

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications